Release date: 2010-08-16
Researchers released a study on the 28th that the body can make rare antibodies that are effective against all influenza viruses, perhaps helping to explore a more effective universal flu treatment.
According to the World Health Organization, seasonal flu can cause an average of 250,000 to 500,000 deaths per year worldwide. Since 2003, 499 people have been infected with the highly lethal but still rare H5N1 avian influenza, of which 295 have died.
The University of Wisconsin-Madison and the University of Tokyo flu expert Kawaoka Yoshihiro said in a statement: "The ability of these antibodies to protect white rats in highly lethal influenza viruses is encouraging." Such antibodies may play a special role in highly curative influenza viruses. â€
The American private health agency Theraclone has identified these flu antibodies using a rare but beneficial antibody technology that can be screened. Since then, the company has signed contracts with researchers to make these antibodies in large quantities and experiment with white mice. Scientists at the University of Wisconsin and the Theraclone Sciences in Seattle say the results of the mouse test show that these immune proteins can help most people get rid of the flu virus dose that normally kills people.
In an article published in the Proceedings of the National Academy of Sciences, the researchers pointed out that when they let the mice containing antibodies infect the deadly H1N1 and H5N1 flu viruses, 60-80% of the mice can recover, and those without antibodies The recovery rate of white mice is only 10%. Researchers say they have the potential to research better versions of antibodies in the laboratory, so-called monoclonal antibodies, to provide better treatments for people with flu-susceptibility.
There are currently four types of flu treatments circulating on the market – Roche and Gilead Science's flu (Tel (Relenza) and two previous drugs, amantadine and rimantadine.
However, the influenza virus is almost resistant to several existing drugs, and several seasonal influenza strains have been mutated, and the flu can no longer be used effectively. Moreover, it is really helpful to have Rexa and flu to be used within two days of infection.
So scientists are looking for better new treatments. Last year, Theraclone and Japan Pharmaceuticals Co., Ltd. signed a $18 million contract to find and produce the antibody. (Source: Medio Medical News)
Spice Novelties Co.,Limited , https://www.wholesale-adult-toys.cn